Overview
ASND market data
Price History
ASND price chart
Valuation & Profitability
- P/E (TTM)
- 26.80 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.76 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.33 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 57.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $186.05 – $282.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $15.4B · P/B 22.43 · P/S 15.35.
Company News
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341Benzinga · Aug 14, 2026, 4:00 PM
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290Benzinga · Aug 14, 2026, 3:25 PM
Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329Benzinga · Aug 14, 2026, 2:18 PM
Full Transcript: Ascendis Pharma Q2 2026 Earnings CallBenzinga · Aug 13, 2026, 1:26 PM
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M EstimateBenzinga · Aug 13, 2026, 11:31 AM
Ascendis Pharma Says Week 78 COACH Data Show TransCon CNP Plus TransCon hGH Combination Tripled Height Z-Score Efficacy vs. Monotherapy In Achondroplasia; Reports Over 170 YUVIWEL US Patient EnrollmentsBenzinga · Aug 6, 2026, 12:11 PM
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275Benzinga · Jul 23, 2026, 6:05 PM
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280Benzinga · Jul 7, 2026, 4:05 PM
Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell MidcapBenzinga · Jun 26, 2026, 8:10 PM
Watching Ascendis Pharma; Shares Spike Higher, Traders Circulate Unconfirmed M&A Blog Comments Suggesting Co In Final Talks To Be AcquiredBenzinga · Jun 25, 2026, 3:00 PM